Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424538 | 0.89 | MAPK1 (0.53) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL3723435 | 0.89 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL29768766 | 0.89 | MAPK1 (0.53) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL1003309 | 0.89 | CLCN2 (0.49) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL30597481 | 0.89 | CLCN2 (0.49) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL1989131 | 0.89 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL6905551 | 0.88 | LMNA (0.55) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL2673723 | 0.88 | RAB9A (0.45) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL16534370 | 0.87 | MAPT (0.50) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL21828877 | 0.87 | HSD17B10 (0.51) | ALDH1A1MEN1KMT2AHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020159436-A1 | WATER CHANNEL AND METHOD OF FORMING SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-08-06 | — | — | WO | claimed |
| EP-4729049-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND AXITINIB AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729052-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND TETRAHYDROCANNABINOL AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-12599610-B2 | Solid dosage formulations of an orexin receptor antagonist | MERCK SHARP & DOHME LLC (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3725778-B2 | FORMULATIONS OF ENZALUTAMIDE | MEDIVATION PROSTATE THERAPEUTICS LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12502357-B2 | Formulations of enzalutamide | ASTELLAS PHARMA INC. (JP) | 2025-12-23 | — | — | US | disclosed |
| US-12447128-B2 | Formulations of enzalutamide | ASTELLAS PHARMA INC. (JP) | 2025-10-21 | — | — | US | disclosed |
| US-20250228840-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | ALDEYRA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250221997-A1 | TYK2 INHIBITOR FORMULATIONS AND METHODS OF MAKING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-10 | — | — | US | disclosed |
| US-20250215002-A1 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | NIMBUS LAKSHMI, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2002011710-A2 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| US-20020006443-A1 | Drug in a solubility-improved form with a concentration-enhancing polymer such as hydroxypropyl methyl cellulose acetate succinate; combination improves bioavailability relative to a control of just solubility improved form | BEND RESEARCH, INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | disclosed |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | disclosed |
| WO-2001068092-A2 | GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001047495-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | disclosed |
| CN-1267753-A | Polyurethane elastic silk and elastic braided fabric | TOYO BOSEKI (JP) | 2000-09-27 | — | — | CN | disclosed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6080833-A | BIS(HYDROXYALKOXYLATED) 1,1'-SPIROBIINDAN POLYCARBONATES AND POLYESTERS POLYMERS AND CURABLE COMPOUNDS SUCH AS BIS(ACRYLATED ALKOXY)SPIROBIINDANS; ALSO POLYAMIDES AND POLYIMIDES CONTAINING SPIROBIINDAN GROUPS | MITSUI CHEMICALS, INC. (JP) | 2000-06-27 | — | — | US | disclosed |
| EP-0822545-A2 | Optical component and spirobiindan polymer therefor | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1998-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599610-B2 | Solid dosage formulations of an orexin receptor antagonist | CRH, HCRTR2, HCRTR1 | ALDH1A1 3659/4885MEN1 3111/4885KMT2A 514/4885 |
| US-12502357-B2 | Formulations of enzalutamide | AR, KLK3, NR5A1 | ALDH1A1 1743/4885MEN1 1023/4885KMT2A 578/4885 |
| US-20250215002-A1 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | TYK2, JAK2, SGK2 | ALDH1A1 4861/4885MEN1 2348/4885KMT2A 250/4885 |
| US-20250221997-A1 | TYK2 INHIBITOR FORMULATIONS AND METHODS OF MAKING THE SAME | TYK2, JAK1, JAK2 | ALDH1A1 4873/4885MEN1 801/4885KMT2A 166/4885 |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | PYGL, PYGM, GYS2 | ALDH1A1 2541/4885MEN1 3048/4885KMT2A 3727/4885 |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | ALDH1A1 3063/4885MEN1 3357/4885KMT2A 3572/4885 |
| US-20250228840-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | SSB, HRH2, ASAH2 | ALDH1A1 1676/4885MEN1 2697/4885KMT2A 2869/4885 |
| US-12447128-B2 | Formulations of enzalutamide | AR, KLK3, NR5A1 | ALDH1A1 1743/4885MEN1 1023/4885KMT2A 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.